Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
respiratory tract diseases | D012140 |
Brand Name | Status | Last Update |
---|---|---|
mekinist | New Drug Application | 2025-08-12 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
non-small-cell lung carcinoma | — | D002289 | — |
melanoma | — | D008545 | — |
Expiration | Code | ||
---|---|---|---|
TRAMETINIB DIMETHYL SULFOXIDE, MEKINIST, NOVARTIS | |||
2030-03-16 | ODE-428 | ||
2026-03-16 | I-908, NP | ||
2025-12-22 | PED | ||
2025-11-04 | PED | ||
2025-10-30 | PED | ||
2025-06-22 | I-895 | ||
2025-05-04 | ODE-183 | ||
2025-04-30 | ODE-182 | ||
2024-12-22 | PED | ||
2024-06-22 | ODE-148 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Trametinib Dimethyl Sulfoxide, Mekinist, Novartis | |||
10869869 | 2033-08-30 | U-3184 | |
8580304 | 2032-01-28 | DP | |
9155706 | 2032-01-28 | DP | |
9271941 | 2032-01-28 | DP | |
9399021 | 2032-01-28 | DP | |
8703781 | 2030-10-15 | DS, DP | U-1712, U-2020, U-2037, U-2302, U-2305, U-3564 |
8952018 | 2030-10-15 | U-2020 | |
7378423 | 2027-05-29 | DS, DP | |
8835443 | 2025-06-10 | U-1581, U-1582, U-2020, U-2037, U-2302, U-2305, U-3564 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Melanoma | D008545 | — | — | 6 | 9 | 5 | 1 | 12 | 30 |
Neoplasms | D009369 | — | C80 | 13 | 15 | 1 | 1 | — | 24 |
Non-small-cell lung carcinoma | D002289 | — | — | 7 | 6 | — | 1 | 2 | 14 |
Lung neoplasms | D008175 | — | C34.90 | 6 | 5 | — | 1 | 2 | 12 |
Glioma | D005910 | EFO_0000520 | — | 2 | 1 | — | 2 | — | 5 |
Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | 1 | — | 3 |
Plexiform neurofibroma | D018318 | EFO_0000658 | — | 1 | 2 | — | 1 | — | 3 |
Astrocytoma | D001254 | EFO_0000271 | — | 1 | 1 | — | 1 | — | 3 |
Oligodendroglioma | D009837 | EFO_0000631 | — | 1 | 1 | — | 1 | — | 3 |
Ganglioglioma | D018303 | — | — | 1 | 1 | — | 1 | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | 1 | 1 | — | — | 3 |
Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | 1 | 1 | — | — | 2 |
Fever | D005334 | — | R50.9 | — | — | 1 | — | — | 1 |
Hyperthermia | D000084462 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 7 | 5 | — | — | — | 9 |
Carcinoma | D002277 | — | C80.0 | 2 | 1 | — | — | 1 | 4 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 3 | — | — | — | 4 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 2 | — | — | — | 3 |
Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | — | 1 | 3 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | — | 3 |
Colonic neoplasms | D003110 | — | C18 | 1 | 1 | — | — | — | 2 |
Adamantinoma | D050398 | — | — | — | 2 | — | — | — | 2 |
Neurofibromatoses | D017253 | — | Q85.00 | 1 | 2 | — | — | — | 2 |
Neurofibroma | D009455 | EFO_0000622 | — | 1 | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Rectal neoplasms | D012004 | — | — | 2 | — | — | — | — | 2 |
Recurrence | D012008 | — | — | 1 | — | — | — | 1 | 2 |
Adenocarcinoma | D000230 | — | — | 2 | — | — | — | — | 2 |
Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
Germ cell and embryonal neoplasms | D009373 | — | — | 1 | — | — | — | — | 1 |
Medulloblastoma | D008527 | — | — | 1 | — | — | — | — | 1 |
Follicular lymphoma | D008224 | — | C82 | 1 | — | — | — | — | 1 |
Rhabdoid tumor | D018335 | — | — | 1 | — | — | — | — | 1 |
Meningioma | D008579 | EFO_0003098 | D32.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Small cell lung carcinoma | D055752 | — | — | — | — | — | — | 1 | 1 |
Hereditary sensory and autonomic neuropathies | D009477 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Trametinib |
INN | trametinib |
Description | Trametinib is a pyridopyrimidine that is used (as its dimethyl sulfoxide addition compound) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, an antineoplastic agent, an anticoronaviral agent and a geroprotector. It is a pyridopyrimidine, an organofluorine compound, an organoiodine compound, a member of acetamides, a ring assembly, a member of cyclopropanes and an aromatic amine. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; MEK (MAPK kinase) inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1 |
PDB | — |
CAS-ID | 871700-17-3 |
RxCUI | — |
ChEMBL ID | CHEMBL2103875 |
ChEBI ID | 75998 |
PubChem CID | 11707110 |
DrugBank | DB08911 |
UNII ID | 33E86K87QN (ChemIDplus, GSRS) |